Factors impeding efficient expression of factor VIII complementary DNA minigenes

Blood Coagulation and Fibrinolysis

Volumn 8, Issue SUPPL. 2, 1997, Pages

  Hoeben, Rob C ^a   Fallaux, Frits J ^a,b   Schagen, Frederik H E ^a   Van Der Eb, Marjolijn M ^a   Van Ormondt, Hans ^a   Van Der Eb, Alex J ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Clotting factor; Gene therapy; Haemophilia; Transcription; Viral vector

Indexed keywords

BLOOD CLOTTING FACTOR 8; COMPLEMENTARY DNA; VIRUS VECTOR;

CELL NUCLEUS MATRIX; CONFERENCE PAPER; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; REPRESSOR GENE;

ANIMALS; DNA, COMPLEMENTARY; FACTOR VIII; GENE EXPRESSION REGULATION; GENE THERAPY; HEMOPHILIA A; HUMANS;

EID: 0031406748     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Kaufman RJ: Developing rDNA products for treatment of hemophilia A. Trends Biotechnol 1991, 9:353-359.
2. Pittman DD, Kaufman RJ: Structure-function relationships of factor VIII elucidated through recombinant DNA technology. Thromb Haemost 1989, 61:161-165.
3. Toole JJ, Knopf JL, Wozney JM, et al.: Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984, 312:342-347.
4. Wood WI, Capon DJ, Simonsen CC, et al.: Expression of active human factor VIII from recombinant DNA clones. Nature 1984, 312:330-337.
5. Gitschier J, Wood WI, Goralka TM, et al.: Characterization of the human factor VIII gene. Nature 1984, 312:326-330.
6. Hoeben RC, van der Jagt RC, Schoute F, et al.: Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer. J Biol Chem 1990, 265:7318-7323.
7. Hoeben RC, Fallaux FJ, Van Tilburg NH, et al.: Toward gene therapy for hemophilia A: long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice. Hum Gene Ther 1993, 4:179-186.
8. Israel DI, Kaufman RJ: Retroviral-mediated transfer and amplification of a functional human factor VIII gene. Blood 1990, 75:1074-1080.
9. Fenjves ES, Yao SN, Kurachi K, Taichman LB: Loss of expression of a retrovirus-transduced gene in human keratinocytes. J Invest Dermatol 1996, 106:576-578.
10. Gerrard AJ, Austen DE, Brownlee GG: Recombinant factor IX secreted by transduced human keratinocytes is biologically active. Br J Haematol 1996, 95:561-563.
11. Gerrard AJ, Hudson DL, Brownlee GG, Watt FM: Towards gene therapy for haemophilia B using primary human keratinocytes. Nat Genet 1993, 3:180-183.
12. Yao SN, Wilson JM, Nabel EG, Kurachi S, Hachiya HL, Kurachi K: Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B. Proc Natl Acad Sci USA 1991, 88:8101-8105.
13. Dwarki VJ, Belloni P, Nijjar T, et al.: Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 1995, 92:1023-1027.
14. Chuah MK, Vandendriessche T, Morgan RA: Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther 1995, 6:1363-1377.
15. Armentano D, Thompson AR, Darlington G, Woo SL: Expression of human factor IX in rabbit hepatocy tes by retrovirus-mediated gene transfer: potential for gene therapy of hemophilia B. Proc Natl Acad Sci USA 1990, 87:6141-6145.
16. Lozier JN, Thompson AR, Hu PC, et al.: Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes. Hum Gene Ther 1994, 5:313-322.
17. Hoeben RC, Einerhand MP, Briët E, van Ormondt H, Valerio D, van der Eb AJ: Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 1992, 67:341-345.
18. Hao QL, Malik P, Salazar R, Tang H, Gordon EM, Kohn DB: Expression of biologically active human factor IX in human hematopoietic cells after retroviral vector-mediated gene transduction. Hum Gene Ther 1995, 6:873-880.
19. Wang JM, Zheng H, Sugahara Y, et al.: Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. Hum Gene Ther 1996, 7:1743-1756.
20. Baru M, Sha'anani J, Nur I: Retroviral-mediated in vivo gene transfer into muscle cells and synthesis of human factor IX in mice. Intervirology 1995, 38:356-360.
21. Yao SN, Smith KJ, Kurachi K: Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice. Gene Ther 1994, 1:99-107.
22. Zatloukal K, Cotten M, Berger M, Schmidt W, Wagner E, Birnstiel ML: In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl Acad Sci USA 1994, 91:5148-5152.
23. Dai Y, Roman M, Naviaux RK, Verma IM: Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 1992, 89:10892-10895.
24. Yao SN, Kurachi K: Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc Natl Acad Sci USA 1992, 89:3357-3361.
25. Fallaux FJ, Hoeben RC: Gene therapy for the hemophilias. Curr Opin Hematol 1996, 3:385-389.
26. Hoeben RC, Fallaux FJ, Cramer SJ, et al.: Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995, 85:2447-2454.
27. Lynch CM, Israel DI, Kaufman RJ, Miller AD: Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993, 4:259-272.
28. Pittman DD, Tomkinson KN, Kaufman RJ: Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem 1994, 269:17329-17337.
29. Kessler CM, Floyd CM, Rick ME, Krizek DM, Lee SL, Gralnick HR: Collagen-factor VIII/von Willebrand factor protein interaction. Blood 1984, 63:1291-1298.
30. Foster PA, Zimmerman TS: Factor VIII structure and function. Blood Rev 1989, 3:180-191.
31. Pittman DD, Marquette KA, Kaufman RJ: Role of the B domain for factor VIII and factor V expression and function. Blood 1994, 84:4214-1225.
32. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ: Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993, 81:2925-2935.
33. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ: A large region (∼95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986, 83:5939-5942.
34. Fallaux FJ, Hoeben RC, Briët E: State and prospects of gene therapy for the hemophilias. Thromb Haemost 1995, 74:266-273.
35. Koeberl DD, Halbert CL, Krumm A, Miller AD: Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. Hum Gene Ther 1995, 6:469-479.
36. Eick D, Berger R, Polack A, Bornkamm GW: Transcription of c-myc in human mononuclear cells is regulated by an elongation block. Oncogene 1987, 2:61-65.
37. Bentley DL, Groudine M: A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature 1986, 321:702-706.
38. Eick D, Bornkamm GW: Transcriptional arrest within the first exon is a fast control mechanism in c-myc gene expression. Nucleic Acids Res 1986, 14:8331-8346.
39. Snyder RC, Miller DM: Regulation of c-myc transcription initiation and elongation. Crit Rev Oncogene 1992, 3:283-291.
40. Van Houten JV, Newlon CS: Mutational analysis of the consensus sequence of a replication origin from yeast chromosome III. Mol Cell Biol 1990, 10:3917-3925.
41. Newlon CS, Theis JF: The structure and function of yeast ARS elements. Curr Opin Genet Dev 1993, 3:752-758.
42. Bode J, Stengert-Iber M, Kay V, Schlake T, Dietz-Pfeilstetter A: Scaffold/matrix-attached regions: topological switches with multiple regulatory functions. Crit Rev Eukaryot Gene Express 1996, 6:115-138.
43. Boulikas T: Chromatin domains and prediction of MAR sequences. Int Rev Cytol 1995, 162A:279-388.
44. Gasser SM, Amati BB, Cardenas ME, Hofmann JF: Studies on scaffold attachment sites and their relation to genome function. Int Rev Cytol 1989, 119:57-96.
45. Cockerill PN, Garrard WT: Chromosomal loop anchorage sites appear to be evolutionarily conserved. FEBS Lett 1986, 204:5-7.
46. Cockerill PN, Garrard WT: Chromosomal loop anchorage of the kappa immunoglobulin gene occurs next to the enhancer in a region containing topoisomerase II sites. Cell 1986, 44:273-282.
47. Cockerill PN, Yuen MH, Garrard WT: The enhancer of the immunoglobulin heavy chain locus is flanked by presumptive chromosomal loop anchorage elements. J Biol Chem 1987, 262:5394-5397.
48. Kas E, Chasin LA: Anchorage of the Chinese hamster dihydrofolate reductase gene to the nuclear scaffold occurs in an intragenic region. J Mol Biol 1987, 198:677-692.
49. Buchman AR, Kimmerly WJ, Rine J, Kornberg RD: Two DNA-binding factors recognize specific sequences at silencers, upstream activating sequences, autonomously replicating sequences, and telomeres in Saccharomyces cerevisiae. Mol Cell Biol 1988, 8:210-225.
50. Mills JS, Kingsman AJ, Kingsman SM: Drosophila ARSs contain the yeast ARS consensus sequence and a replication enhancer. Nucleic Acids Res 1986, 14:6633-6648.
51. Boulikas T: Nature of DNA sequences at the attachment regions of genes to the nuclear matrix. J Cell Biochem 1993, 52:14-22.
52. Razin SV, Vassetzky YS, Hancock R: Nuclear matrix attachment regions and topoisomerase II binding and reaction sites in the vicinity of a chicken DNA replication origin. Biochem Biophys Res Commun 1991, 177:265-270.
53. Adachi Y, Kas E, Laemmli UK: Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions. EMBO J 1989, 8:3997-4006.
54. Bode J, Kohwi Y, Dickinson L, et al.: Biological significance of unwinding capability of nuclear matrix-associating DNAs. Science 1992, 255:195-197.
55. Kohwi-Shigematsu T, Kohwi Y: Torsional stress stabilizes extended base unpairing in suppressor sites flanking immunoglobulin heavy chain enhancer. Biochemistry 1990, 29:9551-9560.
56. Homberger HP: Bent DNA is a structural feature of scaffold-attached regions in Drosophila melanogaster interphase nuclei. Chromosoma 1989, 98:99-104.
57. Fallaux FJ, Hoeben RC, Cramer SJ, et al.: The human clotting factor VIII cDNA contains an autonomously replicating sequence consensus- and matrix attachment region-like sequence that binds a nuclear factor, represses heterologous gene expression, and mediates the transcriptional effects of sodium butyrate. Mol Cell Biol 1996, 16:4264-4272.
58. Schubeler D, Mielke C, Maass K, Bode J: Scaffold/matrix-attached regions act upon transcription in a context-dependent manner. Biochemistry 1996, 35:11160-11169.
59. Palmer TD, Rosman GJ, Osborne WR, Miller AD: Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 1991, 88:1330-1334.
60. Scharfmann R, Axelrod JH, Verma IM: Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA 1991, 88:4626-4630.
61. Connelly S, Smith TA, Dhir G, et al.: In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995, 6:185-193.
62. Connelly S, Gardner JM, McClelland A, Kaleko M: High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther 1996, 7:183-195.
63. Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M: Sustained expression of therapeutic levels of human factor VIII in mice. Blood 1996, 87:4671-4677.
64. Connelly S, Mount J, Mauser A, et al.: Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 1996, 88:3846-3853.
65. Angeletti PC, Engler JA: Tyrosine kinase-dependent release of an adenovirus preterminal protein complex from the nuclear matrix. J Virol 1996, 70:3060-3067.
66. Fredman JN, Engler JA: Adenovirus precursor to terminal protein interacts with the nuclear matrix in vivo and in vitro. J Virol 1993, 67:3384-3395.
67. Schaack J, Ho WY, Freimuth P, Shenk T: Adenovirus terminal protein mediates both nuclear matrix association and efficient transcription of adenovirus DNA. Genes Dev 1990, 4:1197-1208.
68. Bodnar JW, Hanson PI, Polvino-Bodnar M, Zempsky W, Ward DC: The terminal regions of adenovirus and minute virus of mice DNAs are preferentially associated with the nuclear matrix in infected cells. J Virol 1989, 63:4344-4353.
69. Cameron C, Notley C, Hoyle S, et al.: Characterization of the canine factor VIII gene [abstract]. Thromb Haemost 1997, suppl:S570.
70. Elder B, Lakich D, Gitschier J: Sequence of the murine factor VIII cDNA. Genomics 1993, 16:374-379.
71. Pijnappels MI, Briët E, van der Zwet GT, Huisden R, Van Tilburg NH, Eulderink F: Evaluation of the cuticle bleeding time in canine haemophilia A. Thromb Haemost 1986, 55:70-73.
72. Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R. Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency). Blood 1984, 63:451-456.
73. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr: Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995, 10:119-121.
74. Bi L, Sarkar R, Naas T, et al.: Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996, 88:3446-3450.